BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 24862139)

  • 1. Predicting recurrent venous thromboembolism in cancer: is it possible?
    Kyrle PA
    Thromb Res; 2014 May; 133 Suppl 2():S17-22. PubMed ID: 24862139
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Venous thromboembolism in cancer patients.
    Deng A; Galanis T; Graham MG
    Hosp Pract (1995); 2014 Dec; 42(5):24-33. PubMed ID: 25485915
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of a clinical prediction rule for risk stratification of recurrent venous thromboembolism in patients with cancer-associated venous thromboembolism.
    Louzada ML; Carrier M; Lazo-Langner A; Dao V; Kovacs MJ; Ramsay TO; Rodger MA; Zhang J; Lee AY; Meyer G; Wells PS
    Circulation; 2012 Jul; 126(4):448-54. PubMed ID: 22679142
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between anticoagulant treatment duration and risk of venous thromboembolism recurrence and bleeding in clinical practice.
    Kaatz S; Fu AC; AbuDagga A; LaMori J; Bookhart BK; Damaraju CV; Tan H; Schein J; Nutescu E
    Thromb Res; 2014 Oct; 134(4):807-13. PubMed ID: 25127013
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Venous thromboembolism: risk factors for recurrence.
    Zhu T; Martinez I; Emmerich J
    Arterioscler Thromb Vasc Biol; 2009 Mar; 29(3):298-310. PubMed ID: 19228602
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anticoagulation after venous thromboembolism. Deciding on the optimal duration.
    Eichinger S
    Hamostaseologie; 2013 Aug; 33(3):211-7. PubMed ID: 23719863
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictors of recurrent venous thromboembolism and bleeding on anticoagulation.
    Menapace LA; McCrae KR; Khorana AA
    Thromb Res; 2016 Apr; 140 Suppl 1():S93-8. PubMed ID: 27067987
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of venous thromboembolism in cancer patients.
    Petralia GA; Kakkar AK
    Semin Thromb Hemost; 2007 Oct; 33(7):707-11. PubMed ID: 18000799
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Optimal duration of anticoagulation of venous thromboembolism].
    Savina EN; Couturaud F
    J Mal Vasc; 2011 Dec; 36 Suppl 1():S28-32. PubMed ID: 22177766
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient-level meta-analysis: effect of measurement timing, threshold, and patient age on ability of D-dimer testing to assess recurrence risk after unprovoked venous thromboembolism.
    Douketis J; Tosetto A; Marcucci M; Baglin T; Cushman M; Eichinger S; Palareti G; Poli D; Tait RC; Iorio A
    Ann Intern Med; 2010 Oct; 153(8):523-31. PubMed ID: 20956709
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical scores to predict recurrence risk of venous thromboembolism.
    Kyrle PA; Eichinger S
    Thromb Haemost; 2012 Dec; 108(6):1061-4. PubMed ID: 22872143
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The incidence, risk factors, and prognosis of recurrent venous thromboembolism (VTE) in patients with advanced solid cancers receiving anticoagulation therapy after the diagnosis of index VTE.
    Yhim HY; Jang MJ; Kwak JY; Yim CY; Choi WI; Lee YC; Lee JO; Lee KW; Bang SM; Kim SH; Kim YK; Chang HJ; Oh D;
    Thromb Res; 2013 Apr; 131(4):e133-40. PubMed ID: 23399441
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment and secondary prevention of venous thromboembolism in cancer patients. Current strategies and new therapeutic options.
    Ay C; Pabinger I
    Hamostaseologie; 2012; 32(2):139-44. PubMed ID: 21822525
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnosis and initial treatment of venous thromboembolism in patients with cancer.
    Streiff MB
    J Clin Oncol; 2009 Oct; 27(29):4889-94. PubMed ID: 19738109
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Optimum duration of anticoagulant treatment after an episode of venous thromboembolism].
    Couturaud F; Kearon C
    Rev Pneumol Clin; 2008 Dec; 64(6):305-15. PubMed ID: 19084210
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of venous thromboembolism in cancer patients.
    Lee AY
    Best Pract Res Clin Haematol; 2009 Mar; 22(1):93-101. PubMed ID: 19285276
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extended therapy for primary and secondary prevention of venous thromboembolism.
    Conway SE; Marcy TR
    J Pharm Pract; 2010 Aug; 23(4):313-23. PubMed ID: 21507831
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Duration of anticoagulation after venous thromboembolism in real world clinical practice.
    Ageno W; Samperiz A; Caballero R; Dentali F; Di Micco P; Prandoni P; Becattini C; Uresandi F; Verhamme P; Monreal M;
    Thromb Res; 2015 Apr; 135(4):666-72. PubMed ID: 25708926
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predicting the risk of recurrent venous thromboembolism. The Austrian study on recurrent venous thromboembolism (AUREC).
    Kyrle PA; Eischer L
    Hamostaseologie; 2013 Aug; 33(3):201-9. PubMed ID: 23712242
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Venous thromboembolism in patients with cancer: an overview for pharmacists using a case-based approach.
    Pangilinan JM
    J Pharm Pract; 2010 Aug; 23(4):294-302. PubMed ID: 21507829
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.